Cytokinetics
CYTK
390 hedge funds and large institutions have $8.26B invested in Cytokinetics in 2024 Q1 according to their latest regulatory filings, with 105 funds opening new positions, 128 increasing their positions, 120 reducing their positions, and 61 closing their positions.
72% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 61
12% more funds holding
Funds holding: 347 → 390 (+43)
10% more funds holding in top 10
Funds holding in top 10: 20 → 22 (+2)
7% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 120
5% more call options, than puts
Call options by funds: $507M | Put options by funds: $485M
4.67% less ownership
Funds ownership: 119.02% → 114.35% (-4.7%)
15% less capital invested
Capital invested by funds: $9.74B → $8.26B (-$1.49B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$349M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$224M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$162M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$149M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$127M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$298M |
| 2 |
BlackRock
New York
|
-$285M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$194M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$163M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$137M |
CYTK Hedge Fund Activity: Q1 2024 in Review
390 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2024, worth a combined $8.26B — down 15% from $9.74B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new CYTK positions and 61 closed out — a net gain of 44 holders — while 128 added to existing stakes and 120 trimmed.
The largest buyer was Bank of America, adding an estimated $349M. The largest seller was Morgan Stanley, cutting an estimated $298M.
- 390 institutional investors held Cytokinetics (CYTK) as of Q1 2024, up from 347 in Q4 2023.
- Funds reported $8.26B of Cytokinetics stock for Q1 2024, down 15% quarter-over-quarter.
- 105 funds opened new Cytokinetics positions in Q1 2024 and 61 closed out, a net change of +44 holders.
- The largest Cytokinetics buyer in Q1 2024 was Bank of America, an estimated $349M added.
- The largest Cytokinetics seller in Q1 2024 was Morgan Stanley, an estimated $298M sold.
Based on aggregated 13F filings for Q1 2024.